MINI-FUTURE LONG - ELI LILLY & CO | Market Closed - Swiss Exchange 16:20:00 14/06/2024 BST | ||
| 3.36 CHF | +1.51% |
|
| Current month | +18.31% | ||
| 1 month | +46.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 3.36 | +1.51% |
| 13/06/24 | 3.31 | +3.12% |
| 11/06/24 | 3.21 | +1.26% |
| 10/06/24 | 3.17 | +2.59% |
| 07/06/24 | 3.09 | +3.00% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYCMU | |
| ISIN | CH1292908642 |
| Date issued | 01/09/2023 |
| Strike | 506.5 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.7 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.36 CHF |
|---|---|
| Lowest since issue | 0.44 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.30% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- LLYCMU Certificat